[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 313
1. Morency E, Leitao MM Jr, Soslow RA: Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin. Int J Gynecol Pathol; 2016 May;35(3):222-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
  • Many adnexal high-grade serous carcinomas (HGSCs) may derive from microscopic precursors in the fallopian tube.
  • By studying a series of low-stage ovarian carcinomas, we anticipated that HGSCs would be distributed in a pattern suggesting secondary involvement, helping to indirectly validate the fallopian tube origin theory, and that most ovarian carcinomas other than serous carcinomas would demonstrate features consistent with derivation from precursors located in or transplanted to the ovary.
  • Seventy-six patients with low-stage (FIGO I/II) sporadic ovarian carcinoma who underwent primary surgical management at Memorial Sloan Kettering Cancer Center from 1980 to 2000 were included in the study.
  • Histologic type was assigned using Gilks' criteria.
  • Similar to the approach taken when distinguishing primary and metastatic mucinous or endometrioid carcinoma involving ovary, cases interpreted as showing a "primary" pattern of ovarian involvement had ≥3 of the following features: unilateral tumor, size >12 cm, no surface involvement, no multinodularity, and no destructive stromal invasion.
  • Cases comprised HGSC (n=22), endometrioid carcinoma (n=30), clear cell carcinoma (n=13), and mucinous carcinoma (n=11).
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / pathology. Fallopian Tube Neoplasms / pathology. Ovarian Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Dec 15;98(12):2599-606 [14669279.001]
  • [Cites] Int J Gynecol Pathol. 2001 Oct;20(4):323-8 [11603214.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):331-7 [17064757.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1027-34 [8625204.001]
  • [Cites] Gynecol Obstet Invest. 1993;35(3):129-35 [8505002.001]
  • [Cites] Clin Obstet Gynecol. 2012 Mar;55(1):24-35 [22343226.001]
  • [Cites] Gynecol Oncol. 2009 Oct;115(1):108-11 [19615727.001]
  • [Cites] Mod Pathol. 2012 Apr;25(4):625-36 [22193042.001]
  • [Cites] Histopathology. 1995 Oct;27(4):367-71 [8847068.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):265-72 [15213603.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1447-64 [11075847.001]
  • [Cites] Am J Surg Pathol. 2013 Mar;37(3):356-67 [23282975.001]
  • [Cites] Am J Surg Pathol. 2010 Mar;34(3):433-43 [20154587.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 9;247(1-2):4-21 [16297528.001]
  • [Cites] Int J Gynecol Pathol. 2010 May;29(3):203-11 [20407318.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):177-85 [9006334.001]
  • [Cites] Am J Surg Pathol. 1994 Jul;18(7):687-93 [8017563.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):301-6 [15099937.001]
  • [Cites] PLoS One. 2010 Apr 26;5(4):e10358 [20436685.001]
  • [Cites] Int J Gynecol Pathol. 2012 Sep;31(5):423-8 [22833081.001]
  • [Cites] Gynecol Oncol. 2011 Mar;120(3):470-3 [21159368.001]
  • [Cites] Hum Pathol. 2013 Aug;44(8):1534-43 [23465279.001]
  • [Cites] Lancet Oncol. 2012 Apr;13(4):385-94 [22361336.001]
  • [Cites] Int J Gynecol Pathol. 1998 Apr;17 (2):129-34 [9553809.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6116-26 [16144910.001]
  • [Cites] Am J Surg Pathol. 2010 Jun;34(6):829-36 [20431479.001]
  • [Cites] Clin Cancer Res. 2013 Jun 1;19(11):2873-82 [23589176.001]
  • [Cites] Am J Surg Pathol. 2011 Feb;35(2):276-88 [21263249.001]
  • [Cites] Int J Mol Sci. 2013 Mar 06;14(3):5367-79 [23466883.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1810-20 [8961970.001]
  • [Cites] Am J Surg Pathol. 2010 Oct;34(10):1407-16 [20861711.001]
  • [Cites] Am J Surg Pathol. 2009 Mar;33(3):376-83 [19011565.001]
  • [Cites] Am J Surg Pathol. 2012 Mar;36(3):368-75 [22082603.001]
  • (PMID = 26630225.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / WT1 Proteins; 0 / WT1 protein, human
  •  go-up   go-down


2. Rudd ML, Mohamed H, Price JC, O'Hara AJ, Le Gallo M, Urick ME, NISC Comparative Sequencing Program, Cruz P, Zhang S, Hansen NF, Godwin AK, Sgroi DC, Wolfsberg TG, Mullikin JC, Merino MJ, Bell DW: Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1. BMC Cancer; 2014 Nov 26;14:884
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.
  • Most ECs are endometrioid, serous, or clear cell carcinomas, or an admixture of histologies.
  • Serous and clear ECs are clinically aggressive tumors for which alternative therapeutic approaches are needed.
  • The purpose of this study was to search for somatic mutations in the tyrosine kinome of serous and clear cell ECs, because mutated kinases can point to potential therapeutic targets.
  • METHODS: In a mutation discovery screen, we PCR amplified and Sanger sequenced the exons encoding the catalytic domains of 86 tyrosine kinases from 24 serous, 11 clear cell, and 5 mixed histology ECs.
  • For somatically mutated genes, we next sequenced the remaining coding exons from the 40 discovery screen tumors and sequenced all coding exons from another 72 ECs (10 clear cell, 21 serous, 41 endometrioid).
  • We assessed the copy number of mutated kinases in this cohort of 112 tumors using quantitative real time PCR, and we used immunoblotting to measure expression of these kinases in endometrial cancer cell lines.
  • Immunoblotting confirmed TNK2 and DDR1 expression in endometrial cancer cell lines.
  • CONCLUSIONS: This is the first study to systematically search for mutations in the tyrosine kinome in clear cell endometrial tumors.
  • Our findings indicate that high-frequency somatic mutations in the catalytic domains of the tyrosine kinome are rare in clear cell ECs.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Nat Genet. 2011 May;43(5):442-6 [21499247.001]
  • [Cites] J Clin Invest. 2001 Mar;107(6):727-35 [11254672.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(8):2906-17 [11283268.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18392-8 [11278436.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2001 Jun;15(3):433-46 [11476564.001]
  • [Cites] FASEB J. 2001 Dec;15(14):2724-6 [11606478.001]
  • [Cites] Circ Res. 2002 Jun 14;90(11):1147-9 [12065315.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Science. 2002 Jul 5;297(5578):63-4 [12098689.001]
  • [Cites] Hum Cell. 2002 Jun;15(2):81-95 [12227503.001]
  • [Cites] J Am Soc Nephrol. 2002 Nov;13(11):2648-56 [12397034.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Biol Chem. 2004 Oct 15;279(42):44039-45 [15308621.001]
  • [Cites] Acta Obstet Gynaecol Jpn. 1972 Jan;19(1):47-58 [4678779.001]
  • [Cites] Cancer Res. 1978 Nov;38(11 Pt 2):4367-75 [698977.001]
  • [Cites] Clin Obstet Gynecol. 1982 Mar;25(1):5-17 [7039906.001]
  • [Cites] In Vitro. 1983 Mar;19(3 Pt 1):147-58 [6339371.001]
  • [Cites] Gynecol Oncol. 1984 Feb;17(2):213-30 [6706226.001]
  • [Cites] Am J Obstet Gynecol. 1987 Jun;156(6):1486-91 [3591862.001]
  • [Cites] Nature. 1993 May 27;363(6427):364-7 [8497321.001]
  • [Cites] FASEB J. 1999;13 Suppl:S77-82 [10352148.001]
  • [Cites] J Cell Physiol. 2005 Apr;203(1):295-304 [15468059.001]
  • [Cites] Nat Rev Clin Oncol. 2011 May;8(5):261-71 [21221135.001]
  • [Cites] J Biol Chem. 2011 May 20;286(20):17672-81 [21398698.001]
  • [Cites] Biochem J. 2011 Apr 15;435(2):355-64 [21309750.001]
  • [Cites] Clin Cancer Res. 2012 Feb 15;18(4):969-80 [22223527.001]
  • [Cites] Cancer Discov. 2012 May;2(5):401-4 [22588877.001]
  • [Cites] J Natl Cancer Inst. 2012 Oct 3;104(19):1503-13 [22923510.001]
  • [Cites] Genome Res. 2012 Nov;22(11):2120-9 [23028188.001]
  • [Cites] Gynecol Oncol. 2012 Dec;127(3):651-61 [23000148.001]
  • [Cites] Nat Genet. 2012 Dec;44(12):1310-5 [23104009.001]
  • [Cites] Sci Transl Med. 2013 Jan 9;5(167):167ra4 [23303603.001]
  • [Cites] Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21 [23359684.001]
  • [Cites] Sci Signal. 2013 Apr 2;6(269):pl1 [23550210.001]
  • [Cites] Nature. 2013 May 2;497(7447):67-73 [23636398.001]
  • [Cites] PLoS One. 2014;8(6):e63313 [23755103.001]
  • [Cites] J Clin Oncol. 2013 Jul 10;31(20):2607-18 [23733771.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15901-6 [16247015.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):642-6 [16495918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9796-801 [16777958.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37527-35 [17038317.001]
  • [Cites] Mol Biol Cell. 2007 Mar;18(3):732-42 [17182860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8713-7 [18552176.001]
  • [Cites] J Biol Chem. 2009 Mar 20;284(12):8185-94 [19144635.001]
  • [Cites] Mol Cell Biol. 2010 Mar;30(6):1541-54 [20086093.001]
  • [Cites] Nature. 2010 Apr 15;464(7291):993-8 [20393554.001]
  • [Cites] J Cell Physiol. 2010 Aug;224(2):327-33 [20432460.001]
  • [Cites] Anticancer Res. 2010 Apr;30(4):1327-34 [20530448.001]
  • [Cites] N Engl J Med. 2010 Oct 28;363(18):1693-703 [20979469.001]
  • [Cites] BMC Biochem. 2010;11:42 [20979614.001]
  • [Cites] Nat Cell Biol. 2011 Jan;13(1):49-58 [21170030.001]
  • [Cites] Mol Biol Cell. 2011 Apr;22(7):940-53 [21289093.001]
  • [Cites] Clin Obstet Gynecol. 2011 Jun;54(2):245-55 [21508694.001]
  • [Cites] Genes Dev. 2000 Sep 1;14(17):2216-28 [10970885.001]
  • (PMID = 25427824.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA140323; United States / NCI NIH HHS / CA / R01CA140323; United States / NCI NIH HHS / CA / R01CA112021; United States / NCI NIH HHS / CA / R01 CA112021; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / DDR1 protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.2 / TNK2 protein, human; EC 2.7.7.- / DNA Polymerase II; EC 2.7.7.- / POLE protein, human
  • [Other-IDs] NLM/ PMC4258955
  •  go-up   go-down


3. Bukowski RM: Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab. Cancer Manag Res; 2010 Mar 26;2:83-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab.
  • The biology and pathogenesis of clear cell carcinoma of the kidney has been extensively investgated, and the role of von Hipple-Landau gene inactivation and tumor associated angiogenesis is now recognized.
  • Development of vascular endothelial growth factor inhibitors and phase 3 clinical trials utilizing this class of agents has produced a new treatment paradigm for patients with metastatic renal cell carcinoma (RCC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21188099.001).
  • [ISSN] 1179-1322
  • [Journal-full-title] Cancer management and research
  • [ISO-abbreviation] Cancer Manag Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3004565
  • [Keywords] NOTNLM ; bevacizumab / interferon-α / metastatic renal cell carcinoma
  •  go-up   go-down


Advertisement
4. Hong S, Zhang X, Chen J, Zhou J, Zheng Y, Xu C: Targeted gene silencing using a follicle-stimulating hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro. J Ovarian Res; 2013;6(1):80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted gene silencing using a follicle-stimulating hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro.
  • The proliferation, migration and invasion of the ovarian clear cell carcinoma cell line ES-2 were evaluated by cell counting kit-8 assay, cell scratch assay and transwell migration assay.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24252539.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3843555
  •  go-up   go-down


5. Suhail M: Na, K-ATPase: Ubiquitous Multifunctional Transmembrane Protein and its Relevance to Various Pathophysiological Conditions. J Clin Med Res; 2010 Feb;2(1):1-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Na(+), K(+)-ATPase (NKA) is an ubiquitous enzyme consisting of α, β and γ subunits, and is responsible for the creation and maintenance of the Na(+) and K(+) gradients across the cell membrane by transporting 3 Na(+) out and 2 K(+) into the cell.
  • Identification of naturally occurring regulators of  NKA could initiate the discovery of new hormone-like control systems involved in the etiology of selected disease processes, hence the importance of understanding the relation of the sodium pump and its ligands to disease.
  • NKA is also involved in hypertension, salt balance, cardiovascular and renal disorders, sperm capacitation, cell volume regulation, apoptosis, rheumatoid arthritis, sepsis, neurological disorders, lung edema clearance and preeclampsia.
  • NKA enzyme activity and subunit levels are reduced in carcinoma, NKA-β levels were highly reduced in an invasive form of human renal clear cell carcinoma, androgen-dependent prostate cancer, in early stages of urothelial cancer, as well as in poorly differentiated, highly motile carcinoma cell lines obtained from various tissues suggesting a functional link between reduced NKA-β expression and cancer progression.
  • It could be a target for the development of anticancer drugs as it serves as a signal transducer, it is a player in cell adhesion and its aberrant expression and activity are implicated in the development and progression of different cancers.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22457695.001).
  • [ISSN] 1918-3003
  • [Journal-full-title] Journal of clinical medicine research
  • [ISO-abbreviation] J Clin Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3299169
  •  go-up   go-down


6. Alldredge JK, Eskander RN: EZH2 inhibition in <i>ARID1A</i> mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers. Gynecol Oncol Res Pract; 2017;4:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EZH2 inhibition in <i>ARID1A</i> mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers.
  • Clear cell carcinoma and endometrioid adenocarcinoma are histologic subtypes of ovarian and uterine cancer that demonstrate unique clinical behavior but share common underlying genomic aberrations and oncogenic pathways.
  • EZH2 inhibition in <i>ARID1A</i> mutated tumors acts in a synthetically lethal manner to suppress cell growth and promote apoptosis, revealing a unique new therapeutic opportunity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2013 Jun;45(6):592-601 [23644491.001]
  • [Cites] Nat Med. 2016 Feb;22(2):128-34 [26845405.001]
  • [Cites] Science. 2010 Oct 8;330(6001):228-31 [20826764.001]
  • [Cites] Gynecol Oncol. 2013 Feb;128(2):344-8 [22871469.001]
  • [Cites] J Obstet Gynaecol Can. 2017 Jan;39(1):34-41 [28062021.001]
  • [Cites] Neoplasia. 2012 Oct;14(10):986-93 [23097632.001]
  • [Cites] J Pathol. 2011 Jul;224(3):328-33 [21590771.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2004 Apr;18(2):349-71 [15157647.001]
  • [Cites] Mol Cancer Res. 2011 Apr;9(4):418-29 [21383005.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):412-7 [8774649.001]
  • [Cites] Mol Cancer Res. 2010 Dec;8(12 ):1610-8 [21115743.001]
  • [Cites] Mod Pathol. 2013 Aug;26(8):1101-10 [23524907.001]
  • [Cites] Int J Gynecol Cancer. 2014 Mar;24(3):534-40 [24557437.001]
  • [Cites] Nat Chem Biol. 2012 Nov;8(11):890-6 [23023262.001]
  • [Cites] CA Cancer J Clin. 2017 Jan;67(1):7-30 [28055103.001]
  • [Cites] Int J Gynaecol Obstet. 2015 Jul;130(1):27-30 [25912412.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):268-73 [16330673.001]
  • [Cites] Am J Surg Pathol. 2011 May;35(5):625-32 [21412130.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9236-44 [16230384.001]
  • [Cites] Nature. 2014 Jan 23;505(7484):495-501 [24390350.001]
  • [Cites] Oncotarget. 2015 Nov 17;6(36):39088-97 [26384299.001]
  • [Cites] Int J Biol Sci. 2012;8(1):59-65 [22211105.001]
  • [Cites] APMIS. 2010 Mar;118(3):196-202 [20132185.001]
  • [Cites] J Natl Cancer Inst. 2014 Jun 04;106(7):null [24899687.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20380-5 [19091943.001]
  • [Cites] Nature. 2012 Dec 6;492(7427):108-12 [23051747.001]
  • [Cites] Cancer. 1982 Jul 1;50(1):163-70 [7083121.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] Proc Natl Acad Sci U S A. 2012 Dec 26;109 (52):21360-5 [23236167.001]
  • [Cites] Nat Med. 2015 Mar;21(3):231-8 [25686104.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1289-93 [16452181.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6656-61 [18448678.001]
  • [Cites] Cancer Biol Ther. 2010 Oct 15;10 (8):788-95 [20686362.001]
  • [Cites] Virchows Arch. 2012 Jan;460(1):77-87 [22120431.001]
  • [Cites] Int J Clin Oncol. 2015 Oct;20(5):967-73 [25744580.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):903-11 [15696121.001]
  • [Cites] Science. 2002 Nov 1;298(5595):1039-43 [12351676.001]
  • [Cites] Lancet Oncol. 2012 Apr;13(4):385-94 [22361336.001]
  • [Cites] Cancer Res. 2011 Nov 1;71(21):6718-27 [21900401.001]
  • [Cites] N Engl J Med. 2010 Oct 14;363(16):1532-43 [20942669.001]
  • [Cites] Cancer Sci. 2011 Mar;102(3):530-9 [21205084.001]
  • [Cites] J Cancer. 2012;3:129-36 [22408686.001]
  • [Cites] Annu Rev Biochem. 2009;78:273-304 [19355820.001]
  • [Cites] Oncotarget. 2015 Feb 20;6(5):3136-46 [25605014.001]
  • [Cites] Nature. 2013 May 2;497(7447):67-73 [23636398.001]
  • [Cites] Int J Gynecol Cancer. 2013 Jul;23 (6):997-1005 [23792601.001]
  • [Cites] Oncol Rep. 2009 Aug;22(2):233-40 [19578761.001]
  • [Cites] Cancer Biol Ther. 2014 Mar 1;15(3):271-8 [24335192.001]
  • [Cites] Cancer. 1997 May 15;79(10):2052-61 [9149035.001]
  • [Cites] Oncol Lett. 2014 Nov;8(5):2049-2054 [25295088.001]
  • [Cites] Carcinogenesis. 2010 Sep;31(9):1576-83 [20668008.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):355-62 [11606097.001]
  • [Cites] Cancer Cell. 2010 Aug 9;18(2):185-97 [20708159.001]
  • [Cites] Nature. 2015 Apr 9;520(7546):239-42 [25629630.001]
  • [Cites] PLoS One. 2014 Dec 10;9(12 ):e111840 [25493630.001]
  • [Cites] J Gynecol Oncol. 2014 Jan;25(1):58-63 [24459582.001]
  • [Cites] Mod Pathol. 2012 Apr;25(4):615-24 [22157930.001]
  • (PMID = 29093822.001).
  • [ISSN] 2053-6844
  • [Journal-full-title] Gynecologic oncology research and practice
  • [ISO-abbreviation] Gynecol Oncol Res Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Keywords] NOTNLM ; ARID1A / EZH2 / Molecular carcinogenesis / Synthetic lethality / Targeted therapy
  •  go-up   go-down


7. Genega EM, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P, Grisanzio C, Signoretti S: Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol; 2010 Dec;134(6):873-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade.
  • We evaluated its immunohistochemical expression in 317 primary and 42 metastatic renal neoplasms (186 clear cell, 52 papillary, 35 chromophobe, 47 unclassified, and 15 Xp11.2 translocation renal cell carcinomas [RCCs]; 26 oncocytomas; 2 metanephric adenomas; 1 urothelial carcinoma; 1 mixed epithelial and stromal tumor; and 1 angiomyolipoma); 7 neoplasms were unknown as to whether they were primary or metastatic.
  • We also correlated expression with tumor type and grade.
  • Variable staining was seen in clear cell, papillary, unclassified, and Xp11.2 translocation carcinomas.
  • One chromophobe carcinoma had focal expression.
  • An association was found between high expression and clear cell vs non-clear cell carcinomas with all cases (P < .01) and primary (P < .01) cases.
  • An association between CAIX expression and grade (P < .01) in primary clear cell carcinomas was found.
  • CAIX expression is more common in clear cell RCC than other renal tumor types and is associated with grade.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] Med Oncol. 2009;26 Suppl 1:18-22 [19165638.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):802-11 [12576453.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):750-61 [12766578.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):2-7 [12838292.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1398-403 [12854129.001]
  • [Cites] Urol Clin North Am. 2003 Nov;30(4):843-52 [14680319.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6290S-5S [15448019.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Int J Cancer. 1986 Oct 15;38(4):489-94 [2428759.001]
  • [Cites] JAMA. 1995 Feb 15;273(7):564-70 [7837390.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2827-31 [9230182.001]
  • [Cites] J Urol. 1999 Feb;161(2):381-6; discussion 386-7 [9915408.001]
  • [Cites] Curr Oncol Rep. 2005 Mar;7(2):109-15 [15717944.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):640-6 [15832088.001]
  • [Cites] Clin Lab Med. 2005 Jun;25(2):247-57 [15848735.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3714-21 [15897568.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):51-68 [16512599.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5):534-43 [17045082.001]
  • [Cites] Histopathology. 2006 Dec;49(6):594-602 [17163844.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):225-9 [17210525.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4757-64 [17947723.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):241-7 [18941400.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):281-91 [11859199.001]
  • (PMID = 21088149.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA101942; United States / NCI NIH HHS / CA / P50CA101942
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ NIHMS511251; NLM/ PMC3778911
  •  go-up   go-down


8. Nunes TF, Szejnfeld D, Miiji LN, Goldman SM: Isolated metachronous splenic metastasis from renal cell carcinoma after 5 years. BMJ Case Rep; 2012;2012
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated metachronous splenic metastasis from renal cell carcinoma after 5 years.
  • We report the case of a 55-year-old woman with clear cell carcinoma of the kidney, who underwent radical nephrectomy.
  • A splenectomy was performed and histopathological examination of the spleen confirmed the presence of clear cell carcinoma with infiltration of the capsule.
  • This is only the seventh case described in the literature of isolated splenic metastasis from clear cell carcinoma and the first such case containing MRI.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Splenic Neoplasms / diagnosis. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1990 Mar;143(3):468-73; discussion 473-4 [2304155.001]
  • [Cites] J Urol. 1995 Jul;154(1):28-31 [7776446.001]
  • [Cites] Radiology. 2005 Jan;234(1):189-96 [15537838.001]
  • [Cites] Radiographics. 2005 Jul-Aug;25(4):967-82 [16009818.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 May;135(5):667-71 [18936972.001]
  • [Cites] Int J Surg. 2010;8(5):353-5 [20438874.001]
  • [Cites] J Urol. 2010 Apr;183(4):1309-15 [20171681.001]
  • [Cites] CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 [20610543.001]
  • (PMID = 23242082.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4543784
  •  go-up   go-down


9. Cao W, Huang B, Fei X, Huang X, Dai J, Zhou W, Xu Z, Su H, Cheng K, Sun F: Clear cell changes in mucinous tubular and spindle cell carcinoma: cytoplasmic pallor/clearing within tubules, vacuoles or hybrid conventional clear cell carcinoma of kidney? Int J Clin Exp Pathol; 2014;7(7):4350-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell changes in mucinous tubular and spindle cell carcinoma: cytoplasmic pallor/clearing within tubules, vacuoles or hybrid conventional clear cell carcinoma of kidney?
  • Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare and recently recognized subtype of renal cell carcinoma (RCC).
  • Case 1, a 85 years old man, showed numerous vacuoles among inherent components and cytoplasmic pallor/clearing within tubules mimicking conventional clear cell RCC with a 8.5 years follow-up, while Case 2 indicated a "mucin-poor" MTSCC associated with simultaneous conventional clear cell RCC at her age of 73 years.
  • Until now Case 1 carries the longest disease-free survival reported in literature since MTSCC was defined and ranks the oldest since reported in literature, while Case 2 is the first report of "mucin-poor" MTSCC associated with simultaneous conventional clear cell RCC.
  • Now, since no biomarkers or imagining tools but pathological examination can confirm the diagnosis of MTSCC, the management is always following the guideline of RCC in clinical practice.
  • Generally, most reports consider it as a good prognosis disease, but sarcomatoid variant, even classic subtype can progress rapidly to life-threatening disease.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / pathology. Aged, 80 and over. Biomarkers, Tumor / analysis. Cytoplasm / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucins / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2009 Jun;22 Suppl 2:S2-S23 [19494850.001]
  • [Cites] Am J Surg Pathol. 2009 Jan;33(1):44-9 [18941398.001]
  • [Cites] J Clin Oncol. 2010 Oct 1;28(28):e539-40 [20679595.001]
  • [Cites] Ann Diagn Pathol. 2012 Jan;16(1):59-62 [21310639.001]
  • [Cites] Eur Urol. 2012 May;61(5):972-93 [22405593.001]
  • [Cites] Ann Oncol. 2012 Oct;23 Suppl 7:vii65-71 [22997456.001]
  • [Cites] Abdom Imaging. 2012 Oct;37(5):861-72 [22075767.001]
  • [Cites] Indian J Pathol Microbiol. 2012 Oct-Dec;55(4):439-42 [23455776.001]
  • [Cites] Saudi J Kidney Dis Transpl. 2013 May;24(3):557-60 [23640631.001]
  • [Cites] Hum Pathol. 2001 May;32(5):506-12 [11381369.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):281-91 [11859199.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1162-71 [12429795.001]
  • [Cites] Histopathology. 2002 Dec;41(6):549-55 [12460208.001]
  • [Cites] Pathol Int. 2004 Mar;54(3):201-7 [14989744.001]
  • [Cites] Int J Surg Pathol. 2004 Apr;12(2):179-83 [15173928.001]
  • [Cites] Ultrastruct Pathol. 1998 Jan-Feb;22(1):83-90 [9491220.001]
  • [Cites] Pathol Int. 1998 May;48(5):416-20 [9704350.001]
  • [Cites] Clin Lab Med. 2005 Jun;25(2):393-416 [15848743.001]
  • [Cites] Virchows Arch. 2005 Dec;447(6):978-83 [16231179.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):13-9 [16330937.001]
  • [Cites] Am J Clin Pathol. 2006 Jan;125(1):99-104 [16482997.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1554-60 [17122511.001]
  • [Cites] Ann Diagn Pathol. 2007 Feb;11(1):13-21 [17240302.001]
  • [Cites] Hum Pathol. 2008 Jun;39(6):966-9 [18400251.001]
  • [Cites] J Urol. 2010 Feb;183(2):738-9 [20022029.001]
  • (PMID = 25120820.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  • [Other-IDs] NLM/ PMC4129055
  • [Keywords] NOTNLM ; Mucinous tubular and spindle cell carcinoma of the kidney / clear cell carcinoma / prognosis / therapy
  •  go-up   go-down


10. Prat J: Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch; 2012 Mar;460(3):237-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.
  • Malignant epithelial tumors (carcinomas) are the most common ovarian cancers and also the most lethal gynecological malignancies.
  • Based on histopathology and molecular genetic alterations, ovarian carcinomas are divided into five main types (high-grade serous (70%), endometrioid (10%), clear cell (10%), mucinous (3%), and low-grade serous carcinomas (<5%)) that account for over 95% of cases.
  • For a successful specific treatment, reproducible histopathological diagnosis of the tumor cell type is critical.
  • The five tumor types are morphologically diverse and resemble carcinomas of the uterus.
  • Actually, recent investigations have demonstrated that a significant number of cancers, traditionally thought to be primary ovarian tumors (particularly serous, endometrioid, and clear cell carcinomas), originate in the fallopian tube and the endometrium and involve the ovary secondarily.
  • This review summarizes recent advances in the molecular pathology which have greatly improved our understanding of the biology of ovarian carcinoma and are also relevant to patient management.
  • [MeSH-major] Carcinoma / genetics. Carcinoma / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2004 Aug;35(8):934-48 [15297961.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7678-81 [15520168.001]
  • [Cites] Histopathology. 2004 Feb;44(2):109-15 [14764054.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):61-7 [11773283.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1421-8 [16980943.001]
  • [Cites] J Pathol. 2006 Dec;210(4):405-11 [17096315.001]
  • [Cites] Diagn Mol Pathol. 2001 Jun;10(2):116-22 [11385321.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):607-13 [17258789.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] Cancer Res. 1998 May 15;58(10 ):2095-7 [9605750.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):861-70 [12808121.001]
  • [Cites] Nat Med. 2005 Jan;11(1):63-70 [15619626.001]
  • [Cites] Int J Gynecol Cancer. 2009 Apr;19(3):471-9 [19407577.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):605-19 [16021566.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):564-9 [10749912.001]
  • [Cites] Gynecol Oncol. 1996 Feb;60(2):238-44 [8631545.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1707-12 [9563487.001]
  • [Cites] BMC Cancer. 2008 Jan 22;8:17 [18208621.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1239-51 [18602670.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):168-73 [18342932.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):342-6 [10053105.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2 Suppl 1):S23-5 [17027068.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1447-64 [11075847.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1168-74 [17667538.001]
  • [Cites] Am J Surg Pathol. 2011 Dec;35(12):1759-65 [22089527.001]
  • [Cites] Lancet. 2001 Sep 8;358(9284):844 [11570411.001]
  • [Cites] Am J Surg Pathol. 2009 Jan;33(1):14-21 [18830127.001]
  • [Cites] Mod Pathol. 2011 Jun;24(6):846-54 [21317880.001]
  • [Cites] Cancer. 2001 Dec 1;92 (11):2829-36 [11753956.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):910-7 [15297959.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1581-6 [9118042.001]
  • [Cites] Am J Surg Pathol. 2010 Mar;34(3):433-43 [20154587.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Gynecol Oncol. 2011 Oct;123(1):5-12 [21683992.001]
  • [Cites] N Engl J Med. 2010 Oct 14;363(16):1574-5 [20942676.001]
  • [Cites] PLoS One. 2010 Apr 26;5(4):e10358 [20436685.001]
  • [Cites] Nat Rev Cancer. 2010 Nov;10 (11):803-8 [20944665.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:139-48 [16869747.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):139-52 [11812936.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):83-9 [16258507.001]
  • [Cites] Hum Pathol. 2004 Nov;35(11):1360-8 [15668893.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):383-9 [18300813.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):127-32 [15625367.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7052-6 [11156411.001]
  • [Cites] Am J Surg Pathol. 2009 Aug;33(8):1220-4 [19461510.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Obstet Gynecol. 2002 Jan;99(1):3-10 [11777502.001]
  • [Cites] Oncogene. 2010 Feb 25;29(8):1103-13 [19935705.001]
  • [Cites] Annu Rev Pathol. 2009;4:461-87 [18954285.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 6;98(23):1694-706 [17148771.001]
  • [Cites] PLoS Med. 2008 Dec 2;5(12):e232 [19053170.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):625-9 [17320156.001]
  • [Cites] N Engl J Med. 2010 Oct 14;363(16):1532-43 [20942669.001]
  • [Cites] Nature. 2001 Dec 20-27;414(6866):924-8 [11780067.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5198-208 [18698038.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1344-7 [9537226.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):617-35 [10366144.001]
  • [Cites] J Pathol. 2001 Nov;195(4):451-6 [11745677.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):391-400 [12352188.001]
  • [Cites] Hum Pathol. 2011 Jun;42(6):833-9 [21208644.001]
  • [Cites] Am J Surg Pathol. 2008 Dec;32(12):1835-53 [18813124.001]
  • [Cites] Obstet Gynecol. 2002 Aug;100(2):281-7 [12151151.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):527-36 [10433945.001]
  • [Cites] Mod Pathol. 2008 Feb;21(2):131-9 [18084252.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):917-21 [15829967.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Obstet Gynecol. 2006 Aug;108(2):361-8 [16880307.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):904-13 [16508639.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):496-504 [15087669.001]
  • [Cites] Hum Pathol. 2009 Sep;40(9):1213-23 [19552940.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] J Pathol. 2012 Feb;226(3):413-20 [22102435.001]
  • [Cites] Am J Surg Pathol. 2011 Nov;35(11):1605-14 [21997682.001]
  • [Cites] Cancer. 2010 Nov 15;116(22):5261-71 [20665887.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1449-62 [9850171.001]
  • (PMID = 22322322.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement